association (references)

References for: association

Full identifier: http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#association

Nanopublication	Part	Subject	Predicate	Object	Published By	Published On
http://purl.org/np/RAGYO-YzYa... RAGYO-YzYa	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	http://www.w3.org/1999/02/22-rdf-syntax-ns#type type	http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement	Leoni Bücken	2021-06-13T14:37:05.692Z
http://purl.org/np/RAGYO-YzYa... RAGYO-YzYa	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	http://www.w3.org/2000/01/rdf-schema#label label	caspofungin acetate is an echinocandin antifungal indicated in adults and pediatric patients 3 months of age and older for empirical therapy for presumed fungal infections in febrile neutropenic patients 1 treatment of candidemia and the following candida 1 treatment of esophageal candidiasis 1 treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies 1 caspofungin acetate for injection is indicated as empirical therapy for presumed fungal infections in febrile neutropenic adult and pediatric patients 3 months of age and older see clinical studies 14 1 14 5 caspofungin acetate for injection is indicated for the treatment of candidemia and the following candida infections intra abdominal abscesses peritonitis and pleural space infections in adult and pediatric patients 3 months of age and older see clinical studies 14 2 14 5 limitations of use candida caspofungin acetate for injection is indicated for the treatment of esophageal candidiasis in adult and pediatric patients 3 months of age and older see clinical studies 14 3 14 5 limitations of use see clinical studies 14 3 caspofungin acetate for injection is indicated for the treatment of invasive aspergillosis in adult and pediatric patients 3 months of age and older who are refractory to or intolerant of other therapies see clinical studies 14 4 14 5 limitations of use	Leoni Bücken	2021-06-13T14:37:05.692Z
http://purl.org/np/RAGYO-YzYa... RAGYO-YzYa	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	http://www.w3.org/1999/02/22-rdf-syntax-ns#object object	http://purl.obolibrary.org/obo/DOID_13146 DOID_13146	Leoni Bücken	2021-06-13T14:37:05.692Z
http://purl.org/np/RAGYO-YzYa... RAGYO-YzYa	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate	https://w3id.org/biolink/vocab/treats treats	Leoni Bücken	2021-06-13T14:37:05.692Z
http://purl.org/np/RAGYO-YzYa... RAGYO-YzYa	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject	https://identifiers.org/drugbank:DB00520 drugbank:DB00520	Leoni Bücken	2021-06-13T14:37:05.692Z
http://purl.org/np/RAGYO-YzYa... RAGYO-YzYa	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	https://w3id.org/biolink/vocab/association_type association_type	https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation	Leoni Bücken	2021-06-13T14:37:05.692Z
http://purl.org/np/RAGYO-YzYa... RAGYO-YzYa	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	https://w3id.org/biolink/vocab/provided_by provided_by	https://w3id.org/um/NeuroDKG NeuroDKG	Leoni Bücken	2021-06-13T14:37:05.692Z
http://purl.org/np/RAGYO-YzYa... RAGYO-YzYa	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	https://w3id.org/biolink/vocab/relation relation	https://schema.org/TreatmentIndication TreatmentIndication	Leoni Bücken	2021-06-13T14:37:05.692Z